Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | HPGD | P15428 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | USP2 | O75604 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA7 | P43166 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9333497 | 0.89 | TSHR (0.56) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL30079619 | 0.87 | TPMT (0.51) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL1052202 | 0.83 | SMN1; SMN2 (0.48) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL28461177 | 0.83 | KDM4E (0.60) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5219296 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5220237 | 0.82 | TPMT (0.56) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5219287 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL5219283 | 0.82 | KDM4E (0.44) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL3545386 | 0.82 | PPARG (0.55) | KDM4EALDH1A1HPGDGAAMAPT | |
| SCHEMBL9077842 | 0.81 | KDM4E (0.58) | KDM4EALDH1A1HPGDGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | claimed |
| WO-2025067473-A1 | BENZENE RING-CONTAINING COMPOUND HAVING ANALGESIC EFFECT, PREPARATION METHOD THEREFOR, AND USE THEREOF | 四川大学华西医院 | 2025-04-03 | — | — | WO | disclosed |
| US-7253198-B2 | Hydroxyethylamine derivatives for the treatment of Alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2007-08-07 | — | — | US | disclosed |
| EP-1567488-B1 | HYDROXYETHYLAMINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | BROWN TRUMAN R | 2006-04-27 | — | — | US | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1175155-A4 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CT (US) | 2005-10-19 | — | — | EP | disclosed |
| EP-1175155-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000062626-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2000-10-26 | — | — | WO | disclosed |
| US-5514676-A | TO INHIBIT THE FORMATION OF ADVANCED GLYCOSLYATION PRODUCTS BY THE NONENZYMATIC CROSSLINKING OF PROTEINS WITH REDUCING SUGARS, USED IN FOOD PRESERVATION AND TO PREVENT PROTEIN AGING IN COLLAGEN OR LENSES IN THE EYE PRESERVATION | THE ROCKEFELLER UNIVERSITY (US) | 1996-05-07 | — | — | US | disclosed |
| US-4251454-A | MADE FROM ANILINOMETHYLENE CHLORO-AMINO-HYDROCINNAMONITRILE | HOFFMANN-LA ROCHE INC. (US) | 1981-02-17 | — | — | US | disclosed |
| US-4039543-A | SUBSTITUTED BY AMINE, N-RING, AMIDE, CARBAMATE, UREA | HOFFMANN-LA ROCHE INC. (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089316-A1 | Method for reducing a susceptibility to tumor formation induced by 3-deoxyglucosone and precursors thereof | ALDOA, FBP1, GYS2 | KDM4E 1769/4885ALDH1A1 450/4885HPGD 20/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | KDM4E 1129/4885ALDH1A1 3102/4885HPGD 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.